IRIDEX (NASDAQ:IRIX) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of IRIDEX (NASDAQ:IRIX) in a research report report published on Tuesday. The firm issued a hold rating on the medical equipment provider’s stock.

IRIDEX Trading Up 1.9 %

IRIDEX stock opened at $1.64 on Tuesday. IRIDEX has a 12-month low of $1.27 and a 12-month high of $3.65. The stock has a market capitalization of $27.29 million, a PE ratio of -2.45 and a beta of 0.82. The firm has a 50 day simple moving average of $1.72 and a 200-day simple moving average of $1.77. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.54 and a quick ratio of 0.85.

IRIDEX (NASDAQ:IRIX) last announced its quarterly earnings data on Tuesday, November 12th. The medical equipment provider reported ($0.12) earnings per share for the quarter. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%. The firm had revenue of $11.58 million during the quarter. During the same period last year, the business posted ($0.11) EPS.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.